Citi lowered the firm’s price target on Bruker (BRKR) to $38 from $40 and keeps a Neutral rating on the shares after the company reported Q2 results and lowered FY25 guidance, citing weaker than expected end markets, soft demand in China, and tariffs. The firm’s estimates move lower following the guidance cut, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR: